SCHEMBL20744329

SCHEMBL20744329

NS(=O)(=O)CC1CCCCN1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.42
KMT2A Q03164 3/20 0.41
CYP2D6 P10635 2/20 0.41
MEN1 O00255 2/20 0.41
LMNA P02545 2/20 0.41
TP53 P04637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
TSHR P16473 1/20 0.41
MLNR O43193 1/20 0.41
ABCB11 O95342 1/20 0.41
EGFR P00533 1/20 0.41
FYN P06241 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
HTR1A P08908 1/20 0.41
CHRM5 P08912 1/20 0.41
ADRA2A P08913 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CHRM1 P11229 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20744671 0.98 KMT2A (0.44) FDPSKMT2ACYP2D6MEN1LMNA
SCHEMBL25040341 0.94 APLNR (0.36) FDPSKMT2ACYP2D6MEN1LMNA
SCHEMBL20762013 0.94 APLNR (0.36) FDPSKMT2ACYP2D6MEN1LMNA
Hydrochloric Acid SCHEMBL20744622 0.92 KMT2A (0.38) FDPSKMT2ACYP2D6MEN1LMNA
SCHEMBL6391423 0.79 FDPS (0.42) FDPSKMT2ACYP2D6MEN1LMNA
Sulfuric Acid SCHEMBL28199660 0.78 FDPS (0.44) FDPSKMT2ACYP2D6MEN1LMNA
SCHEMBL1921759 0.75
SCHEMBL156067 0.75
SCHEMBL30613 0.75
SCHEMBL1968777 0.73 KMT2A (0.47) FDPSKMT2ACYP2D6MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
US-11773058-B2 Sulfonamide carboxamide compounds INFLAZOME LIMITED (IE) 2023-10-03 US disclosed
US-11773058-B2 Sulfonamide carboxamide compounds INFLAZOME LIMITED (IE) 2023-10-03 US disclosed
US-20200331850-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2020-10-22 US disclosed
EP-3668601-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS Inflazome Limited (IE) 2020-06-24 EP disclosed
WO-2019034696-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 WO disclosed
WO-2019034696-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773058-B2 Sulfonamide carboxamide compounds NLRP3, NOD1, NLRP1 FDPS 2542/4885KMT2A 3406/4885CYP2D6 636/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS FDPS 2178/4885KMT2A 4371/4885CYP2D6 1699/4885
US-20200331850-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 FDPS 2575/4885KMT2A 3719/4885CYP2D6 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.